Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 50,000,000
Countries
Sector(s)
Germany : € 50,000,000
Services : € 50,000,000
Signature date(s)
29/04/2020 : € 25,000,000
29/04/2020 : € 25,000,000

Summary sheet

Release date
24 April 2020
Status
Reference
Signed | 29/04/2020
20190880
Project name
Promoter - financial intermediary
INNOVATIVE CELL THERAPIES (EGFF) (COVID-19)
PLURISTEM GMBH
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 50 million
EUR 100 million
Location
Sector(s)
  • Services - Professional, scientific and technical activities
Description
Objectives

The promoter is a clinical-stage biotherapy company that use placental stem cells and its unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, haematological disorders and mucosal repair following a severe infection, as well as complications from COVID-19 infection.

The proposed transaction will support R&D investments that are required in order to further advance the promoter's product pipeline and bring the products to market.

Environmental aspects
Procurement

The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending 2011/92/EU. Full environmental details will be verified during the appraisal.

The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

Link to source

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Documents

Environmental and Social Data Sheet (ESDS) - INNOVATIVE CELL THERAPIES (EGFF)
Publication Date
24 May 2020
Document language
Main Topic
Lending
Document Number
127656520
Document Focus
Environmental Information
Project Number
20190880
Sector(s)
Regions
Countries
Publicly available
Download now
Environmental and Social Completion Sheet (ESCS) - INNOVATIVE CELL THERAPIES (EGFF) (COVID-19)
Publication Date
1 Nov 2023
Document language
Main Topic
Lending
Document Number
171875362
Document Focus
Environmental Information
Project Number
20190880
Sector(s)
Regions
Countries
Publicly available
Download now
scoreboard - EUROPEAN GROWTH FINANCE FACILITY
Publication Date
13 Sep 2019
Document Language
English
Main Topic
lending
Document Number
122912044
Document Focus
EFSI legal requirements
Document Type
Scoreboard
Project Number
20180667
Last update
19 Aug 2020
Sector(s)
Services
Countries
Bulgaria, Kenya, Ghana, Mexico, Philippines
Publicly available
Download now

News & Stories

Videos

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

Related publications